Ming-Yang Wang

Ming-Yang Wang

Auto-generated profile, based on publicly available information

Ming-Yang Wang

Department of Surgery, National Taiwan University Hospital, Taipei City, Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in European Journal of Radiology
Verified
Journal Article
Closed access
NCNing Chien
Ning Chien
YCYi-Hsuan Cho
Yi-Hsuan Cho
MWMing-Yang Wang
Ming-Yang Wang
LTLi-Wei Tsai
Li-Wei Tsai
CYCheng-Ya Yeh
Cheng-Ya Yeh
YCYeun-Chung Chang
Yeun-Chung Chang

14 December 2022 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
CLCHING-HUNG LIN
CHING-HUNG LIN
MZMuhammad Zahid
Muhammad Zahid
WKWen Hung Kuo
Wen Hung Kuo
FHFu-Chang Hu
Fu-Chang Hu
MWMing-Yang Wang
Ming-Yang Wang
LCLi-Tzong Chen
Li-Tzong Chen
The incidence of breast cancer among premenopausal women has been increasing rapidly in recent decades in East Asia. This case–control study investigated whether estrogen-DNA adducts were associated with breast cancer risk in Taiwan. The control group (n = 146) comprised healthy female volunteers and women with non-proliferative breast disease. The case group (n = 221) comprised women either with proliferative benign breast disease or breast cancer. The ratios of estrogen-DNA adducts to their respective metabolites and conjugates in plasma were analyzed using ultraperformance LC/MS-MS. The SNPs of CYP1A1, CYP1B1, and COMT were genotyped. Logistic regression model was used to compare the estrogen-DNA adduct ratios between the two groups. The estrogen-DNA adduct ratio in the case group was significantly higher than that in the control group (median ratio: 58.52 vs. 29.36, P = 0.004). A multiple logistic regression model demonstrated that a unit increase in the natural log of the estrogen-DNA adduct ratio in premenopausal women was a significant predictor of breast cancer risk, with an estimated hazard ratio of 1.718 (1.444−2.046, P < 0.001). However, the CYP1A1, CYP1B1, and COMT SNPs were not associated with the estrogen-DNA adduct ratios. In conclusion, plasma estrogen-DNA adduct ratio was associated with the presence of breast cancer or proliferating benign breast disease in premenopausal women in Taiwan. Prevention Relevance: This study provides evidence that endogenous estrogen-induced genotoxicity may contribute to the carcinogenesis of breast cancer in premenopausal Asian women. This work could have important preventive implication for the emerging disease in East Asia.

1 July 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
HHHou-Chun Huang
Hou-Chun Huang
HCHsin-Hsiang Chung
Hsin-Hsiang Chung
JYJia-Ying Yu
Jia-Ying Yu
BCBo-Rong Chen
Bo-Rong Chen
MWMing-Yang Wang
Ming-Yang Wang
CHCheng-Chih Hsu
Cheng-Chih Hsu
Background Conventional histopathological examination for breast core needle biopsy diagnosis is time-consuming and labor-intensive, leading to delayed medical treatments and increased psychological burden for patients. A rapid and reliable diagnostic method is needed to assist routine pathological diagnosis. Methods We developed a miniature mass spectrometry platform coupled with paper spray ionization (MiniMaP) for rapid breast cancer diagnosis. This platform enables direct molecular analysis of biopsy samples without sample preparation. A machine learning model was trained to differentiate benign and malignant samples based on molecular profiles. The platform’s performance was further evaluated in a 22-month multicenter validation study. Results Here we show that the machine learning model trained on molecular profiles achieves 88% accuracy in distinguishing breast cancer from benign samples. The model identifies 60 molecular features as potential biomarkers. Additionally, MiniMaP is implemented for on-site analysis in a hospital setting, enabling breast cancer diagnosis within 5 min. The platform maintains consistent accuracy (84%) across 540 biopsy samples over the 22-month validation period. Conclusions Our results demonstrate that the MiniMaP platform enables rapid breast cancer diagnosis and maintains consistent performance in long-term multicenter validation. It holds promise for assisting clinical breast cancer diagnosis by providing instant diagnostic reports to support timely medical decisions and improve medical care.



3 April 2023
Verified
Other
Open access
CLCHING-HUNG LIN
CHING-HUNG LIN
MZMuhammad Zahid
Muhammad Zahid
WKWen Hung Kuo
Wen Hung Kuo
FHFu-Chang Hu
Fu-Chang Hu
MWMing-Yang Wang
Ming-Yang Wang
LCLi-Tzong Chen
Li-Tzong Chen
Supplementary Table S2: The ratios of estrogen-DNA adduct by participant subgroups